| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447413 | European Journal of Cancer | 2011 | 8 Pages |
Abstract
Extended schedule escalated dose Temozolomide (7Â days on 7Â days off) is feasible and has an acceptable safety profile, but does not improve OS and PFS in metastatic melanoma when compared to standard dose dacarbazine.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Poulam M. Patel, Stefan Suciu, Laurent Mortier, Wim H. Kruit, Caroline Robert, Dirk Schadendorf, Uwe Trefzer, Cornelis J.A. Punt, Reinhard Dummer, Neville Davidson, Juergen Becker, Robert Conry, John A. Thompson, Wen-Jen Hwu, Kristel Engelen,